Bridging the gap between data and public health needs. In the heat of a signal: Responding to a vaccine safety signal for febrile seizures after 2010-11 influenza vaccine in young children, United States

Vaccine

Volumn 30, Issue 11, 2012, Pages 2032-2034

  Broder, Karen R ^a   Martin, David B ^b   Vellozzi, Claudia ^a  

^a NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^b CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; PNEUMOCOCCUS VACCINE; 13 VALENT PNEUMOCOCCAL VACCINE; 13-VALENT PNEUMOCOCCAL VACCINE;

CHILDHOOD DISEASE; DISEASE ASSOCIATION; DRUG LABELING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FEBRILE CONVULSION; FOOD AND DRUG ADMINISTRATION; HEALTH CARE NEED; HIGH RISK POPULATION; HUMAN; INFLUENZA VACCINATION; MEDICAL INFORMATION; NOTE; PRIORITY JOURNAL; PUBLIC HEALTH; PUBLIC HEALTH SERVICE; RISK ASSESSMENT; UNITED STATES; ARTICLE; CHEMICALLY INDUCED DISORDER; INFANT; POSTMARKETING SURVEILLANCE; PRESCHOOL CHILD; VACCINATION;

ADVERSE DRUG REACTION REPORTING SYSTEMS; CENTERS FOR DISEASE CONTROL AND PREVENTION (U.S.); CHILD, PRESCHOOL; HUMANS; INFANT; INFLUENZA VACCINES; PNEUMOCOCCAL VACCINES; PRODUCT SURVEILLANCE, POSTMARKETING; RISK ASSESSMENT; SEIZURES, FEBRILE; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; VACCINATION;

EID: 84857188396     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.12.040     Document Type: Note

References (20)

1. Leroy Z., Broder K.R., Menschik D., Shimabukuro T., Martin D. Febrile seizure reports to the vaccine Adverse Event Reporting System after 2010-11 trivalent inactivated influenza vaccine. Vaccine 2012, 30:2020-2023.
2. Tse A., Tseng H.F., Greene S., Vellozzi C., Lee G. Signal identification and evaluation for risk of febrile seizures in children following trivalent inactivated influenza vaccine in children in the Vaccine Safety Datalink Project, 2010-11. Vaccine 2012, 30:2024-2031.
3. Fiore A., Uyeki T., Broder K., Finelli L., Euler G.L., Singleton J.A., et al. Prevention and control of influenza with vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2010, 59(RR08):1-62.
4. Report of CIOMS Working Group VIII, Practical aspects of signal detection in pharmacovigilence. Geneva; 2010.
5. Salmon D., Pavia A., Gellin B. Editors' introduction: vaccine safety throughout the product life cycle. Pediatrics 2011, 127:S1-S4.
6. Salmon D., Akhtar A., Mergler M., Vannice K.S., Izurieta H., Ball R., et al. Immunization-safety monitoring systems for the 2009 H1N1 monovalent influenza vaccination program. Pediatrics 2011, 127:S78-S86.
7. CDC Update: recommendations of the Advisory Committee on Immunization Practices (ACIP) regarding use of CSL seasonal influenza vaccine (Afluria) in the United States During 2010-11. MMWR Morb Mortal Wkly Rep 2010, 59(31):989-992.
8. Jones T., Jacobsen S.J. Childhood febrile seizures: overview and implications. Int J Med Sci 2007, 4(2):110-114.
9. Barlow W.E., Davis R.L., Glasser J.W., Rhodes P.H., Thompson R.S., Mullooly J.P., et al. The risk of seizures after receipt of whole-cell pertussis or measles, mumps, and rubella vaccine. N Engl J Med 2001, 345:656-661.
10. Greene S.K., Kulldorff M., Lewis E.M., Li R., Yin R., Weintraub E.S., et al. Near real-time surveillance for influenza vaccine safety: proof-of-concept in the Vaccine Safety Datalink Project. Am J Epidemiol 2010, 171:177-188.
11. Vaccine Adverse Event Reporting System, available at, [accessed 18.05.11]. http://vaers.hhs.gov/index.
12. Nuorti P., Whitney C. Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2010, 59(RR11):1-18.
13. CDC Invasive pneumococcal disease and 13-valent pneumococcal conjugate vaccine (PCV13) coverage among children aged≤59 months - selected U.S. regions, 2010-2011. MMWR Morb Mortal Wkly Rep 2011, 60(43):1477-1481.
14. CDC. Influenza vaccination coverage. FluVaxView, available at [accessed 22.11.11]. http://www.cdc.gov/flu/professionals/vaccination/vaccinecoverage.htm.
15. FDA. Fluzone vaccine safety: FDA and CDC update on fluzone influenza vaccine and vaers reports of febrile seizures in children, January 20, 2011, available at [accessed 31.07.11]. http://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/VaccineSafety/ucm240037.htm.
16. FDA. Potential signals of serious risks/new safety information identified from the Adverse Event Reporting System (AERS), available at [accessed 12.05.11]. http://www.fda.gov/drugs/guidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/ucm082196.htm.
17. Advisory Committee on Immunization Practices. Presentation slides February 2011, June 2011, and October 2011 meeting. Available at [Accessed 21.12.11]. http://www.cdc.gov/vaccines/recs/acip/.
18. Kroger T., Sumaya C.V., Pickering L.K., Atkinson W.L. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep 2011, 60(RR02):1-60.
19. FDA. Vaccines licensed for immunization and distribution in the US with supporting documents. Available at [accessed 01.08.11]. http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm093830.htm.
20. CDC. Vaccine information statements. Available at [accessed 01.08.11]. http://www.cdc.gov/vaccines/pubs/vis/default.htm.